A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 14 Jul 2017 Planned End Date changed from 31 Mar 2017 to 31 Dec 2018.
- 14 Jul 2017 Planned primary completion date changed from 31 Mar 2017 to 31 Dec 2018.
- 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.